Chimeric antigen receptor T-cell therapy for relapsed/refractory primary cutaneous B-lymphoblastic lymphoma with rapid and durable systemic regression.
APA
Gan X, Wu Y, et al. (2026). Chimeric antigen receptor T-cell therapy for relapsed/refractory primary cutaneous B-lymphoblastic lymphoma with rapid and durable systemic regression.. The British journal of dermatology, 194(4), 797-799. https://doi.org/10.1093/bjd/ljaf484
MLA
Gan X, et al.. "Chimeric antigen receptor T-cell therapy for relapsed/refractory primary cutaneous B-lymphoblastic lymphoma with rapid and durable systemic regression.." The British journal of dermatology, vol. 194, no. 4, 2026, pp. 797-799.
PMID
41637061
같은 제1저자의 인용 많은 논문 (5)
- Multi-omics analysis of the lactylation-driven microenvironment and non-invasive clinical translation in hepatocellular carcinoma.
- Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma.
- An interpretable machine learning model for predicting visceral pleural invasion in cT1 lung adenocarcinoma based on habitat analysis.
- Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial.
- Design, synthesis, and evaluation of cyclic C7-bridged monocarbonyl curcumin analogs containing an -methoxy phenyl group as potential agents against gastric cancer.